Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Chemical Communications (Cambridge, England)|July 26, 2008
Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrationsKaterina Capková, Mark S Hixon, Laura A McAllister, et al.Chemical Communications (Cambridge, England)|October 2, 2003
The first Pummerer cyclisations on solid phase. Convenient construction of oxindoles enabled by a sulfur-link to resinLaura A McAllister, Stephen Brand, Rémy de Gentile, et al.The Journal of Organic Chemistry|August 12, 2006
Solid phase approaches to N-heterocycles using a sulfur linker cleaved by SmI2Laura A McAllister, Kristy L Turner, Stephen Brand, et al.Bioconjugate Chemistry|February 24, 2007
Synthesis and application of a novel ligand for affinity chromatography based removal of endotoxin from antibodiesLaura A McAllister, Mark S Hixon, Roberta Schwartz, et al.Journal of the American Chemical Society|March 30, 2006
Superactivation of the botulinum neurotoxin serotype A light chain metalloprotease: a new wrinkle in botulinum neurotoxinLaura A McAllister, Mark S Hixon, Jack P Kennedy, et al.Chemistry (Weinheim an Der Bergstrasse, Germany)|January 4, 2007
A fluorous, Pummerer cyclative-capture strategy for the synthesis of N-heterocyclesLaura A McAllister, Rosemary A McCormick, Karen M James, et al.Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Antibody-catalyzed anaerobic destruction of methamphetamineYang Xu, Mark S Hixon, Noboru Yamamoto, et al.Journal of Combinatorial Chemistry|July 11, 2006
Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitorsGrant E Boldt, Jack P Kennedy, Mark S Hixon, et al.Journal of Combinatorial Chemistry|July 11, 2006
Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formationYang Xu, Hong Lu, Jack P Kennedy, et al.ACS Chemical Biology|October 9, 2014
Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environmentJan-Philip Schülke, Laura A McAllister, Kieran F Geoghegan, et al.Pageof 3